HHS Nominee Price's Stock Picks To Surface At Confirmation Hearings

Questions about US Health and Human Services Secretary nominee Tom Price's investments over the last year – including in Zimmer Biomet – and overlapping legislation he has introduced are likely to be raised at confirmation hearing before the Senate HELP Committee this week. However, Zimmer Biomet and other device firms have been trying to profit from the business models that Price opposes.

Leaders of a key US Senate health committee are expected to grill incoming President Donald Trump's pick for Health and Human Services Secretary, Rep. Tom Price, R-Ga., this week about his investments in health-care firms over the past year, including in the orthopedic device firm Zimmer Biomet Holdings Inc.

Among the issues that have been raised is that the HHS Secretary-nominee purchased between $1,001 to $15,000 worth of Zimmer Biomet shares in March 2016, according to congressional records, about the same time he introduced H.R. 4848, the Healthy Inpatient Procedures (HIP) Act (Also see "Fierce Critic Of Obamacare, Medicare Delivery Reforms Tapped To Run HHS" - Medtech Insight, 29 November, 2016.), which calls for a delay in CMS's

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By 

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.

Don’t Sleep On Inspections: Experts Warn FDA Maintains Enforcement Resources

 

Manufacturers of medical products would be foolish to think that recent upheavals at the US FDA will result in a lack of inspections in the coming years. A panel of experts discussed the current state of inspections during a webinar hosted by the Food and Drug Law Institute.

Global Medtech Guidance Tracker: April 2025

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. 25 documents have been posted on the tracker since its last update.